Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Long-Term Investments (2021 - 2025)

Coeptis Therapeutics Holdings has reported Long-Term Investments over the past 4 years, most recently at $7.9 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $7.9 million for Q4 2025, up 38.11% from a year ago — trailing twelve months through Dec 2025 was $7.9 million (up 38.11% YoY), and the annual figure for FY2025 was $7.9 million, up 38.11%.
  • Long-Term Investments for Q4 2025 was $7.9 million at Coeptis Therapeutics Holdings, up from $6.9 million in the prior quarter.
  • Over the last five years, Long-Term Investments for COEPW hit a ceiling of $75.8 million in Q1 2022 and a floor of $5.7 million in Q3 2024.
  • Median Long-Term Investments over the past 4 years was $33.0 million (2022), compared with a mean of $37.3 million.
  • Biggest five-year swings in Long-Term Investments: crashed 56.45% in 2022 and later skyrocketed 38.11% in 2025.
  • Coeptis Therapeutics Holdings' Long-Term Investments stood at $75.8 million in 2021, then tumbled by 56.09% to $33.3 million in 2022, then crashed by 82.89% to $5.7 million in 2024, then skyrocketed by 38.11% to $7.9 million in 2025.
  • The last three reported values for Long-Term Investments were $7.9 million (Q4 2025), $6.9 million (Q3 2025), and $6.9 million (Q2 2025) per Business Quant data.